PARP1 and ovarian carcinoma: We attempted to ascertain the clinical actionability of somatic alterations of BRCA1/2, mutations/deletions/amplification in other HR repair pathway genes, PTEN genomic alterations or PTEN loss, and germline BRCA1/2 mutations beyond breast or ovarian cancer, as it pertains to sensitivity to the PARP inhibitor talazoparib.